Noetik Raises $14M in Seed Financing
Summary
The company intends to use the funds to support it internal data generation efforts and the continued development of transformer-based machine learning methods, as well as to expand Its team in machine learning, computational biology, and cancer immunology. Led by Ron Alfa, M.D., Ph.D. and CEO, and Jacob Rinaldi, Ph.D., CSO, Noetik is an AI-native biotechnology company that has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to tackle fundamental problems in cancer immunology. In less than 12 months of operations, the company has generated human data across a data stack that includes genomics, transcriptomics, and proteomics to enable the development of foundation models for cell and tissue biology. Noetik’s founding leadership team includes Lacey Padron, Ph.D., Chief Technical Officer, who was previously VP Informatics at the Parker Institute for Cancer Immunotherapy. At the Parker Institute, Padron focused on using integrated multiomic data analysis to uncover biomarkers, mechanisms of action, and novel therapies from cancer immunotherapy patient data.